Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window And in this ...

Lung cancer is the second-most common cancer and the leading cause of cancer death in the United States. Over 80% of lung ...

In a study published in The Journal of Clinical Investigation, University of Michigan researchers found a new protein target ...

A China-developed KRAS inhibitor led to objective responses in half of patients with previously treated KRAS-mutant non-small cell lung cancer (NSCLC), a prospective non-randomized trial showed.

CURE spoke with Dr. Alexander Spira to learn what patients need to know about the KRAS G12C mutation and its treatment strategies. Knowledge of the KRAS G12C mutations can be very important for ...

When treated with KRAS inhibitors alone, cancer cells can escape destruction by using the salvage pathway to gather ...

The Oncologic Drug Advisory Committee will review data to determine if Lumakras should gain FDA approval for certain patients with KRAS G12C-mutant non-small cell lung cancer. A panel of experts will ...

Pharmacogenomics. 2014;15(11):1507-1518. MEK/CDK4 PD-0325901 (MEKi) + palbociclib (CDK4i) NCT02022982 MEK/CDK4 Trametinib (MEKi) + palbociclib (CDK4i) NCT02065063 Representative KRAS-directed ...

Please provide your email address to receive an email when new articles are posted on . Significant median PFS improvement with adagrasib over docetaxel for pretreated NSCLC. Treatment-related adverse ...

Mirati Therapeutics said Monday that its KRAS-targeting cancer drug called adagrasib combined with another immunotherapy was well-tolerated by patients with lung cancer — avoiding the serious liver ...

What eventually becomes a graduate student’s PhD thesis work is rarely the project they initially pursued. However, in rare cases like with recent PhD graduate Dr. April Lo from Dr. Alice Berger’s Lab ...